A detailed history of Janus Henderson Group PLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 18,038 shares of RCUS stock, worth $265,158. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,038
Previous 18,038 -0.0%
Holding current value
$265,158
Previous $274,000 0.36%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$14.59 - $18.48 $3,180 - $4,028
-218 Reduced 1.19%
18,038 $274,000
Q1 2024

May 15, 2024

SELL
$14.83 - $20.18 $444 - $605
-30 Reduced 0.16%
18,256 $344,000
Q4 2023

Feb 14, 2024

SELL
$13.43 - $19.63 $470 - $687
-35 Reduced 0.19%
18,286 $349,000
Q3 2023

Nov 14, 2023

BUY
$17.62 - $23.54 $70 - $94
4 Added 0.02%
18,321 $328,000
Q2 2023

Aug 14, 2023

SELL
$16.97 - $22.03 $407 - $528
-24 Reduced 0.13%
18,317 $372,000
Q1 2023

May 15, 2023

BUY
$15.96 - $23.15 $292,722 - $424,594
18,341 New
18,341 $334,000
Q3 2022

Nov 14, 2022

SELL
$23.23 - $30.07 $2,183 - $2,826
-94 Reduced 1.16%
8,002 $209,000
Q2 2022

Aug 15, 2022

BUY
$17.23 - $37.73 $2,102 - $4,603
122 Added 1.53%
8,096 $205,000
Q1 2022

May 16, 2022

SELL
$28.92 - $41.83 $202 - $292
-7 Reduced 0.09%
7,974 $252,000
Q4 2021

Feb 14, 2022

BUY
$31.38 - $48.47 $250,443 - $386,839
7,981 New
7,981 $323,000
Q1 2020

May 14, 2020

SELL
$8.78 - $19.28 $2.6 Million - $5.71 Million
-296,000 Closed
0 $0
Q4 2019

Feb 18, 2020

SELL
$7.33 - $10.79 $1.5 Million - $2.21 Million
-204,654 Reduced 40.88%
296,000 $2.99 Million
Q3 2019

Nov 14, 2019

SELL
$6.44 - $10.18 $44,275 - $69,987
-6,875 Reduced 1.35%
500,654 $4.56 Million
Q2 2019

Jul 31, 2019

BUY
$7.29 - $13.38 $4,964 - $9,111
681 Added 0.13%
507,529 $4.04 Million
Q1 2019

Apr 30, 2019

SELL
$8.95 - $12.49 $3,499 - $4,883
-391 Reduced 0.08%
506,848 $6.33 Million
Q4 2018

Feb 06, 2019

BUY
$9.74 - $14.5 $359,766 - $535,586
36,937 Added 7.85%
507,239 $5.46 Million
Q3 2018

Nov 09, 2018

BUY
$10.88 - $14.95 $8,562 - $11,765
787 Added 0.17%
470,302 $6.56 Million
Q2 2018

Aug 10, 2018

BUY
$12.24 - $17.05 $11,358 - $15,822
928 Added 0.2%
469,515 $5.75 Million
Q1 2018

May 14, 2018

BUY
$15.44 - $17.71 $7.23 Million - $8.3 Million
468,587 New
468,587 $7.24 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.06B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.